DK1334123T3 - Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme - Google Patents

Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme

Info

Publication number
DK1334123T3
DK1334123T3 DK01993708T DK01993708T DK1334123T3 DK 1334123 T3 DK1334123 T3 DK 1334123T3 DK 01993708 T DK01993708 T DK 01993708T DK 01993708 T DK01993708 T DK 01993708T DK 1334123 T3 DK1334123 T3 DK 1334123T3
Authority
DK
Denmark
Prior art keywords
diagnosis
treatment
cell division
proliferative diseases
eukaryotic cell
Prior art date
Application number
DK01993708T
Other languages
Danish (da)
English (en)
Inventor
Pierre Goenczy
Steven Jones
Christophe Echeverri
Anthony Hyman
Karen Oegema
Matthew Kirkham
Original Assignee
Cenix Bioscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix Bioscience Gmbh filed Critical Cenix Bioscience Gmbh
Application granted granted Critical
Publication of DK1334123T3 publication Critical patent/DK1334123T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK01993708T 2000-11-09 2001-11-09 Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme DK1334123T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24675000P 2000-11-09 2000-11-09
PCT/EP2001/013034 WO2002038805A2 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
DK1334123T3 true DK1334123T3 (da) 2009-01-12

Family

ID=22932039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01993708T DK1334123T3 (da) 2000-11-09 2001-11-09 Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme

Country Status (9)

Country Link
US (1) US7368248B2 (enExample)
EP (1) EP1334123B1 (enExample)
JP (1) JP2004526421A (enExample)
AT (1) ATE405585T1 (enExample)
AU (2) AU2002224838B9 (enExample)
CA (1) CA2428438C (enExample)
DE (1) DE60135482D1 (enExample)
DK (1) DK1334123T3 (enExample)
WO (1) WO2002038805A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
WO2005049846A2 (en) * 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9708619B2 (en) 2005-09-20 2017-07-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRNA
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
CA2784783C (en) 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
AU2002224838B2 (en) 2006-07-27
JP2004526421A (ja) 2004-09-02
CA2428438A1 (en) 2002-05-16
DE60135482D1 (de) 2008-10-02
EP1334123A2 (en) 2003-08-13
US20040048277A1 (en) 2004-03-11
AU2483802A (en) 2002-05-21
ATE405585T1 (de) 2008-09-15
CA2428438C (en) 2012-09-25
US7368248B2 (en) 2008-05-06
EP1334123B1 (en) 2008-08-20
WO2002038805A8 (en) 2007-07-05
AU2002224838B9 (en) 2007-02-08
WO2002038805A3 (en) 2003-02-13
WO2002038805A2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DK1334123T3 (da) Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme
IL258880A (en) Diarylhydantoin compounds
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
NO20081211L (no) Xantinderivater som selektive HM74A agonister
UA85559C2 (en) Aminobenzophenone compounds
TR200302309T4 (tr) Fosfodiesterazın yararlı inhibitörleri olarak beta-karbolin türevleri.
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ATE496905T1 (de) Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
DE602004029904D1 (de) Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
NO20052928L (no) Nye kjemiske forbindelser
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
EP1575580A4 (en) METHOD FOR TREATING CARCINOMA
NO20061292L (no) Heterosyldiske forbindelser og fremgangsmater for fremstilling og anvendelse derav
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
NO20075227L (no) Treatment of eczemas
EP1768679A4 (en) MODULATION OF GSK-3B AND METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit